1,813 results match your criteria Expert Review of Anti-infective Therapy[Journal]


A cross-sectional study evaluating the knowledge and beliefs about, and the use of antibiotics amongst medical students in Malaysia.

Expert Rev Anti Infect Ther 2019 Feb 14. Epub 2019 Feb 14.

a Faculty of Medicine and Defense Health , Universiti Pertahanan Nasional Malaysia (National Defense University of Malaysia) , Kem Sungai Besi, 57000 Kuala Lumpur , Malaysia .

Background And Aims: The introduction of antibiotics into modern medicine has changed clinical care by saving millions of lives. However, antibiotics are not a panacea for everything and misuse of antibiotics has led to their many benefits being overshadowed by the development of antimicrobial resistance. This study aimed to assess university students' knowledge and beliefs about and their use of antibiotics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1581607DOI Listing
February 2019

A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: findings and implications.

Expert Rev Anti Infect Ther 2019 Feb 12. Epub 2019 Feb 12.

h Faculty of Pharmacy and Health sciences , University of Balochistan , Quetta , Pakistan.

Objectives: In line with the recent global action plan for antimicrobial resistance, this is the first time such a comprehensive survey has been undertaken in Pakistan, sixth most populous country.

Methods: This point prevalence survey (PPS) was conducted in 13 hospitals among 7 different cities of Pakistan. The survey included all inpatients receiving an antibiotic on the day of PPS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1581063DOI Listing
February 2019

Non-antibiotic therapies for sepsis: an update.

Expert Rev Anti Infect Ther 2019 Feb 12. Epub 2019 Feb 12.

a Dept of Intensive Care, Erasme Hospital , Université libre de Bruxelles , Brussels , Belgium.

Introduction: Sepsis, defined as infection plus some degree of organ dysfunction, is still associated with high mortality and morbidity rates. Management focuses on three key areas: infection control, hemodynamic stabilization and organ support, and modulation of the sepsis response. Areas covered: This review will not cover infection control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1581606DOI Listing
February 2019

Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right?

Expert Rev Anti Infect Ther 2019 Feb 9. Epub 2019 Feb 9.

b Hospital Clinic , Institut d'Investigacions Biomediques August Pi Suner (IDIBAPS) , Barcelona , Spain .

Introduction: The use of palivizumab for the prevention of respiratory syncytial virus-related hospitalization is well-established and has been adopted universally in pediatric position statements. Areas covered: The definition of chronic lung disease (CLD, bronchopulmonary dysplasia) has evolved over time and has significantly impacted the reported incidence of the condition, and the description of mild, moderate and severe disease in published studies. We reviewed lung function in infancy, childhood and adulthood of healthy preterm infants and those with CLD and how alterations in airway function, especially following respiratory syncytial virus infection may set the stage for chronic obstructive pulmonary disease in adults. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2019.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2019.1581062DOI Listing
February 2019
3 Reads

Bridging the digital health divide: toward equitable global access to mobile health interventions for people living with HIV.

Expert Rev Anti Infect Ther 2019 Feb 5. Epub 2019 Feb 5.

a Department of Medicine , University of Virginia School of Medicine , Charlottesville , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1578649DOI Listing
February 2019

Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America.

Expert Rev Anti Infect Ther 2019 Feb 4:1-13. Epub 2019 Feb 4.

a ISGlobal, Hospital Clínic , Universitat de Barcelona , Barcelona , Spain.

Introduction: Chagas disease, caused by infection with the parasite Trypanosoma cruzi, represents a huge public health problem in the Americas, where millions of people are affected. Despite the availability of two drugs against the infection (benznidazole and nifurtimox), multiple factors impede their effective usage: (1) gaps in patient and healthcare provider awareness; (2) lack of access to diagnosis; (3) drug toxicity and absence of treatment algorithms to address adverse effects; (4) failures in drug supply and distribution; and (5) inconsistent drug efficacy against the symptomatic chronic stage. Areas covered: We review new approaches and technologies to enhance access to diagnosis and treatment to reduce the disease burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1577731DOI Listing
February 2019
1 Read

Ocular Chlamydia trachomatis infection: elimination with mass drug administration.

Expert Rev Anti Infect Ther 2019 Jan 30. Epub 2019 Jan 30.

a Dana Center for Preventive Ophthalmology , Johns Hopkins Medical Institutions.

Introduction: Ocular Chlamydia trachomatis infection, the causative agent for trachoma, is responsible for 1.9 million cases of visual loss world-wide. Mass Drug Administration (MDA) with azithromycin to entire trachoma-endemic districts is part of the World Health Organization's public health strategy for trachoma elimination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1577136DOI Listing
January 2019

Ozenoxacin: a review of preclinical and clinical efficacy.

Expert Rev Anti Infect Ther 2019 Jan 28:1-10. Epub 2019 Jan 28.

a Red Española de Investigación en Patología Infecciosa (REIPI) , Madrid , Spain.

Introduction: Impetigo is the most common bacterial skin infection in children. Treatment is becoming complicated due to the development of antimicrobial resistance, especially in the main pathogen, Staphylococcus aureus. Ozenoxacin, a novel non-fluorinated topical quinolone antimicrobial, has demonstrated efficacy in impetigo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1573671DOI Listing
January 2019

Management of febrile neutropenia in special consideration of the role of antimicrobial de-escalation.

Expert Rev Anti Infect Ther 2019 Jan 28. Epub 2019 Jan 28.

d Department of Hematology and Oncology , Medical Center, Otto-von-Guericke University , Magdeburg , Germany .

Introduction: Infections are among the most frequent complications in patients with hematological and oncological diseases. They might be classified as fever of unknown origin, and microbiologically or clinically documented infections. Optimal duration of antimicrobial treatment is still unclear in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1573670DOI Listing
January 2019

Antibiotic stewardship in sepsis management: toward a balanced use of antibiotics for the severely ill patient.

Expert Rev Anti Infect Ther 2019 Feb 23;17(2):89-97. Epub 2019 Jan 23.

a Department of Critical Care Medicine , Ghent University Hospital , Gent , Belgium.

Introduction: Severe infections in critically ill patients carry a high morbidity and mortality rate. Given the impact of early and broad-spectrum empirical therapy in several studies and the emphasis on this in international guidelines, there is a low threshold for initiating antibiotics in many patients with suspected infection. This has led to the widespread use of antibiotics in critically ill patients, which is often unnecessary or inappropriate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1568239DOI Listing
February 2019
1 Read

Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?

Expert Rev Anti Infect Ther 2019 Jan 22:1-10. Epub 2019 Jan 22.

g 3rd Department of Internal Medicine, SOTIRIA Hospital , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: The intravenous (IV) formulation of fosfomycin has been re-introduced in clinical practice mainly to overcome treatment failures against multidrug-resistant (MDR) bacteria. Appropriate dosing schedules of the IV formulation have not yet been established. Areas covered: The mechanism of action and resistance development, commercial IV formulations, pharmacokinetic/pharmacodynamic (PK/PD) properties, IV dosing regimens for the treatment of MDR infections along with efficacy and safety issues were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1573669DOI Listing
January 2019
2 Reads

Late-onset sepsis caused by Gram-negative bacteria in very low birth weight infants: a systematic review.

Expert Rev Anti Infect Ther 2019 Jan 14:1-12. Epub 2019 Jan 14.

a University Children's Hospital , University of Wuerzburg , Wuerzburg , Germany.

Introduction: Very low birth weight (VLBW) infants are highly susceptible to late-onset sepsis (LOS). Compared to Gram-positive bacteria, Gram-negative bacteria are less common to cause LOS, but are associated with a more severe clinical manifestation, higher mortality, and increased risk of neonatal morbidity. So far, the clinical picture of late-onset Gram-negative sepsis (LOGNS) in VLBW infants has not been elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1568871DOI Listing
January 2019
2 Reads

The treatment of melioidosis: is there a role for repurposed drugs? A proposal and review.

Expert Rev Anti Infect Ther 2019 Jan 10:1-11. Epub 2019 Jan 10.

a CBR Division , DSTL Porton Down , Salisbury , Wiltshire , UK.

Introduction: Melioidosis is a significant health problem within endemic areas such as Southeast Asia and Northern Australia. The varied presentation of melioidosis and the intrinsic antibiotic resistance of Burkholderia pseudomallei, the causative organism, make melioidosis a difficult infection to manage. Often prolonged courses of antibiotic treatments are required with no guarantee of clinical success. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1496330DOI Listing
January 2019
4 Reads

Cross-programmatic consultation on the role of primary care in the responsible use of medicines and the reduction of antimicrobial resistance.

Expert Rev Anti Infect Ther 2019 Feb 10;17(2):75-78. Epub 2019 Jan 10.

a WHO Regional Office for Europe , Copenhagen , Denmark.

This meeting was held from the 30 October to the 1 November 2018 in Almaty, Kazakhstan. The meeting brought together participants from 16 countries of central Asia, Caucasus, eastern Europe and expert speakers from western Europe and India. Participants discussed the analysis and use of data on antimicrobial medicines consumption, country experiences in enforcing legislation for prescription-only access to antibiotics, the role of primary health care (PHC) in tackling antimicrobial resistance (AMR), strategies to improving competencies of practitioners using evidence-based clinical protocols and public engagement in the responsible use of medicines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1563482DOI Listing
February 2019
3.461 Impact Factor

Monkeypox re-emergence in Africa: a call to expand the concept and practice of One Health.

Expert Rev Anti Infect Ther 2019 Feb 21;17(2):129-139. Epub 2019 Jan 21.

a US Centers for Disease Control and Prevention, Poxvirus and Rabies Branch , Atlanta , GA , USA.

Introduction: Monkeypox is a re-emerging viral zoonosis that occurs naturally in heavily forested regions of West and Central Africa. Inter-human transmission of monkeypox virus, although limited, drives outbreaks, particularly in household and health-care settings. But the available evidence suggests that without repeated zoonotic introductions, human infections would eventually cease to occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1567330DOI Listing
February 2019
4 Reads

Urinary antigen testing in community-acquired pneumonia in adults: an update.

Expert Rev Anti Infect Ther 2019 Feb 9;17(2):107-115. Epub 2019 Jan 9.

d Department of Infectious Diseases , Hospital Universitari de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), University of Barcelona , Barcelona , Spain.

Introduction: Community-acquired pneumonia (CAP) continues to be a leading cause of hospitalization and mortality worldwide. Streptococcus pneumoniae and Legionella pneumophila remain the major etiological agents and are responsible for a significant proportion of CAP mortality. Among diagnostic tests for CAP, urine antigen detection of S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1565994DOI Listing
February 2019
1 Read

Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology.

Expert Rev Anti Infect Ther 2019 Feb 30;17(2):99-105. Epub 2018 Dec 30.

a Department of Medicine , University of Udine and Azienda Sanitaria Universitaria Integrata , Udine , Italy.

Introduction: Bloodstream infections (BSI) and their evolution to sepsis or septic shock are one of the most important causes of morbidity and mortality; for this reason, arapid recognition and diagnosis of these infections are crucial to improve patients' outcome. Area covered: Procalcitonin (PCT) is considered an important biomarker for diagnosis of infection, routinely used to identify patients developing severe bacterial infections. In this scenario, management of BSI is complicated by the increasing rate of multidrug-resistantstrains, and an early recognition of severe infections is mandatory. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1562335DOI Listing
February 2019
6 Reads

Real life experiences in HCV management in 2018.

Expert Rev Anti Infect Ther 2019 Feb 15;17(2):117-128. Epub 2019 Jan 15.

ab Department of Experimental and Clinical Medicine and Department of Oncology, Interdepartmental Hepatology Center MASVE , Azienda Ospedaliero-Universitaria Careggi (AOUC) , Florence , Italy.

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1563755DOI Listing
February 2019
8 Reads

Efficacy and safety of antimicrobial de-escalation as a clinical strategy.

Expert Rev Anti Infect Ther 2019 Feb 28;17(2):79-88. Epub 2018 Dec 28.

a Assistance Publique Hôpitaux de Marseille, Service d'anesthésie et de réanimation , Aix-Marseille Université , Marseille , France.

Introduction: De-escalation is a widely recommended strategy in regard to guidelines, with an associated adherence to guidelines being around 50%. This review discusses data supporting de-escalation and possible obstacles for its implementation. Areas covered: Although it does not have a consensual definition, de-escalation consists of reducing the spectrum of empirical antimicrobial treatment based on the microbiological findings. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2019.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2019.1561275DOI Listing
February 2019
11 Reads

Improving the rates of Aspergillus detection: an update on current diagnostic strategies.

Expert Rev Anti Infect Ther 2019 Jan 17;17(1):39-50. Epub 2018 Dec 17.

d Division of Infectious Diseases, Department of Medicine , University of California-San Diego , San Diego , CA , USA.

Introduction: The spectrum of disease caused by Aspergillus spp. is dependent on the immune system of the host, and ranges from invasive aspergillosis (IA) to chronic pulmonary aspergillosis (CPA). Early and reliable diagnosis of Aspergillus disease is important to decrease associated morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1558054DOI Listing
January 2019
2 Reads

Management of bacterial skin and skin structure infections with polymicrobial etiology.

Expert Rev Anti Infect Ther 2019 Jan 7;17(1):17-25. Epub 2018 Dec 7.

b Department of Infectious Diseases , AORN dei Colli , Naples , Italy.

Introduction: Skin and Soft Tissue Infections (SSTIs) are some of the most commonly occurring bacterial infections, with a wide range of possible etiological pathogens and a considerable variety of clinical presentations and severity; from mild to severe life-threatening infections. Several classifications have been proposed based on a specific variable, such as anatomical localization, skin extension, progression rate, clinical presentation, severity, and etiological agent. Areas covered: The last criteria allows the differentiation of SSTIs as monomicrobial and polymicrobial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1552518DOI Listing
January 2019
1 Read

Current research toward optimizing dosing of first-line antituberculosis treatment.

Expert Rev Anti Infect Ther 2019 Jan 12;17(1):27-38. Epub 2018 Dec 12.

a Division of Clinical Pharmacology, Department of Medicine , University of Cape Town , Cape Town , South Africa.

Introduction: Drug concentrations in tuberculosis patients on standard regimens vary widely with clinically important consequences. Areas covered: We review the available literature identifying factors correlated with pharmacokinetic variability of antituberculosis drugs. Based on population pharmacokinetic models and the weight, height, and sex distributions in a large data base of African tuberculosis patients, we propose simplified weight-based doses of the available fixed dose combination(FDC) for adults with drug susceptible tuberculosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1555031DOI Listing
January 2019
1 Read
3.461 Impact Factor

Oxfendazole: a promising agent for the treatment and control of helminth infections in humans.

Expert Rev Anti Infect Ther 2019 Jan 10;17(1):51-56. Epub 2018 Dec 10.

e Department of International Health , Johns Hopkins Bloomberg School of Public Health , Baltimore , MD , USA.

Introduction: Oxfendazole (methyl [5-(phenylsulphinyl)-1H benzimidazole-2-yl] carbamate) has a particularly long metabolic half-life in ruminants, and its metabolite fenbendazole also has anthelminthic action. A very limited number of drugs are available for the treatment of some zoonotic helminth infections, such as neurocysticercosis and echinococcosis. More recent work has expanded oxfendazole's nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1555241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376865PMC
January 2019
1 Read
3.461 Impact Factor

Hypervirulent Klebsiella pneumoniae: a new public health threat.

Expert Rev Anti Infect Ther 2019 Feb 5;17(2):71-73. Epub 2018 Dec 5.

a Department of Medicine , University at Buffalo-State University of New York , Buffalo , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1555470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349525PMC
February 2019

Understanding the economic impact of leishmaniasis on households in endemic countries: a systematic review.

Expert Rev Anti Infect Ther 2019 Jan 12;17(1):57-69. Epub 2018 Dec 12.

b Early Detection and Prevention Section , International Agency for Research on Cancer , Lyon , France.

Introduction: Leishmaniasis is a poverty-related disease that causes a significant socioeconomic burden to affected households. Visceral leishmaniasis is fatal if untreated, yet illness costs may lead to delays in accessing care. Skin manifestations of leishmaniasis cause a psychological burden and even longer treatment trajectories. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1555471DOI Listing
January 2019
14 Reads

Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.

Expert Rev Anti Infect Ther 2019 Jan 7;17(1):5-15. Epub 2018 Dec 7.

a Division of Pharmaceutical, Administrative and Social Sciences , Duquesne University School of Pharmacy , Pittsburgh , PA , USA.

Introduction: Community-acquired bacterial pneumonia (CABP) represents a significant clinical and financial burden within infectious disease. In the advent of increasing resistance from bacteria such as Streptococcus pneumoniae to available antibiotic therapies, there is a need for new drugs with novel mechanisms to treat such infections. Areas covered: Lefamulin, the first semi-synthetic pleuromutilin for systemic administration, is nearing completion of Phase III studies for CABP; the manufacturer plans to file for a new drug application (NDA) in Q4 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1554431DOI Listing
January 2019
12 Reads

Teixobactin: a novel anti-infective agent.

Expert Rev Anti Infect Ther 2019 Jan 20;17(1):1-3. Epub 2018 Nov 20.

a Weill Cornell Medical College, Division of General Internal Medicine , New York-Presbyterian Hospital , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2019.1550357DOI Listing
January 2019

The surviving sepsis controversy: a call to action for hospital medicine.

Expert Rev Anti Infect Ther 2018 Dec 14;16(12):889-892. Epub 2018 Nov 14.

a Division of General Internal Medicine, Department of Medicine , Weill Cornell Medical College , New York , NY , USA.

Introduction: There remains significant controversy behind the Surviving Sepsis Campaign Guidelines, as evidenced by the Infectious Diseases Society of America refusing to endorse the latest iteration put forth by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine. An important stakeholder in this debate has not yet been adequately represented: hospitalists. Areas covered: In this perspective piece, we review the key points in this controversy; specifically, the current guidelines for the identification and management of sepsis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1547192DOI Listing
December 2018

Update on current approaches to diagnosis and treatment of onychomycosis.

Expert Rev Anti Infect Ther 2018 Dec 13;16(12):929-938. Epub 2018 Nov 13.

b Division of Dermatology, Department of Medicine , University of Toronto School of Medicine , Toronto , Canada.

Introduction: Onychomycosis is a chronic fungal infection of the nail bed, matrix or plate. It accounts for roughly 50% of all nail disease. As the prevalence of onychomycosis is increasing, a critical review of diagnostic techniques and treatment options is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1544891DOI Listing
December 2018

Non-targeted HIV testing in the emergency department: not just how but where.

Expert Rev Anti Infect Ther 2018 Dec 20;16(12):893-905. Epub 2018 Nov 20.

a Infectious Diseases Service , Lausanne University Hospital , Lausanne , Switzerland.

Introduction: The emergency department (ED) has the potential to enhance early HIV diagnosis through HIV testing programs. How these are implemented is a subject of debate. Areas covered: We describe the main HIV testing approaches: diagnostic testing, targeted screening, and non-targeted screening, and review ED-based non-targeted HIV screening studies conducted after 2006 among ≥5000 patients. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1545575DOI Listing
December 2018
8 Reads

Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?

Expert Rev Anti Infect Ther 2018 Dec 9;16(12):907-912. Epub 2018 Nov 9.

a Hepatobiliary Division, Department of Internal Medicine , Kaohsiung Medical University Hospital , Kaohsiung , Taiwan.

Introduction: Chronic hepatitis C (CHC) genotype-3 (G-3) infection is the next most prevalent genotype with 54.3 million patients globally. It is associated with an increasing risk of fibrosis, liver-related events, hepatocellular carcinoma, and overall mortality. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1544492DOI Listing
December 2018
10 Reads

Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults.

Expert Rev Anti Infect Ther 2018 Dec 14;16(12):877-887. Epub 2018 Nov 14.

a Department of Infectious and Tropical Diseases , University of Brescia and ASST Spedali Civili Hospital , Brescia , Italy.

Introduction: New strategies for HIV treatment are being investigated to reduce drug-exposure, toxicities, and costs. Dolutegravir (DTG) 50 mg/rilpivirine (RPV) 25 mg was approved in November 2017 by FDA and in May 2018 by the European Medicines Agency (EMA). It is indicated as a complete regimen for HIV-1 infected adults with undetectable plasmatic HIV-RNA for at least 6 months on their current HIV treatment combination. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1544491DOI Listing
December 2018
5 Reads

Risk of infection associated with anti-TNF-α therapy.

Expert Rev Anti Infect Ther 2018 Dec 7;16(12):939-956. Epub 2018 Nov 7.

a Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas12), School of Medicine , Universidad Complutense , Madrid , Spain.

Introduction: The advent, more than two decades ago, of monoclonal antibodies and soluble receptors targeting tumor necrosis factor (TNF)-α has revolutionized the therapeutic approach to otherwise difficult-to-treat autoimmune and inflammatory diseases. However, due to the pleiotropic functions played by this pro-inflammatory cytokine (with particular relevance in granuloma maintenance), TNF-α blockade may increase the incidence of serious infections. Areas covered: The present review summarizes the biological rationale supporting the impact of anti-TNF-α therapy on the host's susceptibility to infection. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1544490DOI Listing
December 2018
5 Reads

Overview of prevention and management of acute bronchiolitis due to respiratory syncytial virus.

Expert Rev Anti Infect Ther 2018 Dec 9;16(12):913-928. Epub 2018 Nov 9.

a Paediatric Intensive Care, Paediatric Intensive Care Unit , St. Mary's Hospital , London , UK.

Introduction: Respiratory Syncytial Virus (RSV) is the most common cause of Acute Bronchiolitis (AVB) in infants. AVB causes significant morbidity and mortality worldwide, most deaths occurring in the developing world. AVB causes respiratory distress in infants, leading to respiratory failure in some cases. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1543589DOI Listing
December 2018
3 Reads

Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.

Expert Rev Anti Infect Ther 2018 Dec 5;16(12):865-876. Epub 2018 Nov 5.

a Department of Internal Medicine , University of Michigan Medical School , Ann Arbor , MI , USA.

Introduction: Complicated urinary tract infections are increasingly caused by multidrug-resistant organisms. Carbapenem-resistant Enterobacteriaceae (CRE) constitute a rising threat among uropathogens with significant morbidity and mortality. Meropenem-vaborbactam is a novel carbapenem and cyclic boronic acid-based beta-lactamase inhibitor combination with potent activity against subtypes of CRE. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1542300DOI Listing
December 2018
1 Read

Management of complex tuberculosis cases: a focus on drug-resistant tuberculous meningitis.

Expert Rev Anti Infect Ther 2018 Nov;16(11):813-831

a Department of Neurology , King George Medical University , Lucknow , India.

Introduction: Drug-resistant tuberculous meningitis has been reported worldwide. Isoniazid mono-resistance is the most frequent cause of drug-resistant tuberculous meningitis, a life-threatening disease. Extensive drug-resistant tuberculous meningitis has also been reported in some isolated case reports. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1540930DOI Listing
November 2018
13 Reads

Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options.

Expert Rev Anti Infect Ther 2018 Nov 29;16(11):833-838. Epub 2018 Oct 29.

a Dipartimento di Scienze Mediche e Chirurgiche, Centro Studi e Ricerca sulle Epatiti , Università di Bologna , Bologna , Italy.

Introduction: Direct acting antivirals have completely changed the landscape of the treatment of chronic hepatitis C. The management of the few patients who relapse to direct acting antivirals requires a careful analysis of the chances to achieve therapeutic success with a second antiviral course. In this context, the usefulness of viral resistances testing, able to detect resistance-associated substitutions in the viral sequence, is at present a matter of debate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1538783DOI Listing
November 2018

Candidemia in the cancer patient: diagnosis, treatment, and future directions.

Expert Rev Anti Infect Ther 2018 Nov 16;16(11):849-854. Epub 2018 Oct 16.

b Transplantation-Oncology Infectious Diseases Program, Medical Mycology Research Laboratory, Pediatrics, and Microbiology & Immunology , Weill Cornell Medical Center , New York , NY , USA.

Introduction: The presence of Candida species in the blood is known as candidemia and may constitute a medical emergency for patients with cancer. Despite advances in diagnosis and treatment of this fungal infection, mortality remains unacceptably high. Areas covered: This paper reviews recent advances in molecular diagnostics to detect species of Candida as well as novel antifungal agents that have been developed to address candidiasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1536546DOI Listing
November 2018
1 Read

Using a quality improvement approach to improve care for latent tuberculosis infection.

Expert Rev Anti Infect Ther 2018 10;16(10):737-747

a Montreal Chest Institute , McGill University , Montreal , QC , Canada.

Introduction: Latent tuberculosis infection (LTBI) management is recognized as a key component of the World Health Organization End Tuberculosis Strategy. The term 'cascade of care in LTBI' has recently been used to refer to the process of LTBI management from identification of persons who may have LTBI to completion of treatment. Large gaps throughout the LTBI cascade of care have been identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1521269DOI Listing
October 2018

Iclaprim: a differentiated option for the treatment of skin and skin structure infections.

Expert Rev Anti Infect Ther 2018 Nov 23;16(11):793-803. Epub 2018 Oct 23.

c Department of Medicine , Duke University Medical Center , Durham , NC , USA.

Introduction: Iclaprim is a selective bacterial dihydrofolate reductase (DHFR) inhibitor. Although there are alternative options for the treatment of acute bacterial skin and skin structure infections (ABSSSI), iclaprim is differentiated from other available antibiotics. Areas covered: Iclaprim is under clinical development for ABSSSI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1536545DOI Listing
November 2018
3 Reads

Current anti-biofilm strategies and potential of antioxidants in biofilm control.

Expert Rev Anti Infect Ther 2018 Nov 17;16(11):855-864. Epub 2018 Oct 17.

a School of Science , Monash University Malaysia , Bandar Sunway , Selangor , Malaysia.

Introduction: Biofilm formation is a strategy for microorganisms to adapt and survive in hostile environments. Microorganisms that are able to produce biofilms are currently recognized as a threat to human health. Areas covered: Many strategies have been employed to eradicate biofilms, but several drawbacks from these methods had subsequently raised concerns on the need for alternative approaches to effectively prevent biofilm formation. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1535898DOI Listing
November 2018
4 Reads

Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.

Expert Rev Anti Infect Ther 2018 Nov 10;16(11):805-812. Epub 2018 Oct 10.

a Department of Medicine , Institute of Medical Sciences, Banaras Hindu University , Varanasi , India.

Introduction: Visceral leishmaniasis (VL) is a fatal parasitic disease caused by a parasite belonging to the Leishmania donovani complex and transmitted by infected female Phlebotomous argentipes sand flies. The VL elimination strategy in the Indian subcontinent (ISC), which has a current goal of reducing the incidence of VL to below 1/10,000 of population by the year 2020, consists of rapid detection and treatment of VL to reduce the number of human reservoirs as well as vector control using indoor residual spraying (IRS). However, as the incidence of VL declines toward the elimination goal, greater targeting of control methods will be required to ensure appropriate early action to prevent the resurgence of VL. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1532790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345646PMC
November 2018
3 Reads

Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis.

Expert Rev Anti Infect Ther 2018 Nov 4;16(11):839-847. Epub 2018 Oct 4.

g Pulmonary Intensive Care Unit , Respiratory Institute, Hospital Clinic of Barcelona, IDIBAPS , Barcelona , Spain.

Introduction: Invasive candidiasis is the most common fungal infection affecting critically ill adults. International guidelines provide differing recommendations for first-line antifungal therapy, with echinocandins considered first-line in the majority. Amphotericin B has broad activity and low minimum inhibitory concentration resistance patterns across most Candida species and guidance away from its use should be supported by the available evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1528872DOI Listing
November 2018

The role of extended infusion β-lactams in the treatment of bloodstream infections in patients with liver cirrhosis.

Expert Rev Anti Infect Ther 2018 10 26;16(10):771-779. Epub 2018 Sep 26.

a Infectious Diseases Unit, Department of Medical and Surgical Sciences, Sant'Orsola Hospital , Alma Mater University of Bologna , Bologna , Italy.

Introduction: Bloodstream infections (BSIs) in patients with liver cirrhosis are associated with significant morbidity and mortality. Early appropriated antibiotic treatment is essential for the correct management of these patients. Areas covered: This review covers several aspects of how the pharmacokinetic/pharmacodynamic behavior of antimicrobials may change in patients with liver cirrhosis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1523716DOI Listing
October 2018
10 Reads

The uncertainties of the diagnosis and treatment of a suspected urinary tract infection in elderly hospitalized patients.

Expert Rev Anti Infect Ther 2018 10 26;16(10):763-770. Epub 2018 Sep 26.

b Department of Internal Medicine B , Laniado Hospital, Netanya, Israel;and Ruth and Bruce Rappaport School of Medicine , Haifa , Israel.

Introduction: The diagnostic criteria for a urinary tract infection (UTI) and proper treatment of elderly patients hospitalized with nonspecific symptoms is uncertain. Areas covered: A nonsystematic literature review of the variable approaches in diagnosing and treating hospitalized elderly patients with a suspected UTI. Expert commentary: Bacteriuria and/or pyuria cannot confirm the diagnosis of a UTI because of the high prevalence in the elderly regardless of presentation so urine cultures are not indicated in those hospitalized for diseases outside the urinary tract. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1523006DOI Listing
October 2018
2 Reads

Future of Helicobacter pylori and its feasibility.

Expert Rev Anti Infect Ther 2018 10 17;16(10):733-735. Epub 2018 Sep 17.

b Department of Medical Microbiology , University Medical Center Utrecht , Utrecht , Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1523715DOI Listing
October 2018

Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control.

Expert Rev Anti Infect Ther 2018 10 19;16(10):749-761. Epub 2018 Sep 19.

a Department of Medicine , University of Udine and Azienda Sanitaria Universitaria Integrata , Udine , Italy.

Introduction: Management of antimicrobial resistance in multi-drug-resistant-Klebsiella pneumoniae (MDR-KP) is a major challenge for clinicians. The optimal treatment option for MDR-KP infections is still not well established. Combination therapies including high-dose meropenem, colistin, fosfomycin, tigecycline, and aminoglycosides are widely used, with suboptimal results. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1522249DOI Listing
October 2018
5 Reads

Viral infections in the biologic therapy era.

Expert Rev Anti Infect Ther 2018 10 24;16(10):781-791. Epub 2018 Sep 24.

c Infectious Diseases Unit , Hospital Universitario 12 de Octubre , Madrid , Spain.

Introduction: The development of biologic therapies for treating patients with rheumatic, hematologic, or oncological diseases has increased in the last few years, spreading their use in clinical practice. Areas covered: Clinical experience has evidenced substantial risks for some viral infections and/or reactivations such as viral hepatitis, herpetic infections, and other viruses, as a consequence of specific immune pathway blockages. Biological therapies produce a variable risk of reactivation of viral infections, which is particularly uncertain in the case of the most recently introduced agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1521270DOI Listing
October 2018
17 Reads

Prevalence of tuberculosis and multidrug resistant tuberculosis in the Middle East Region.

Expert Rev Anti Infect Ther 2018 09 13;16(9):709-721. Epub 2018 Sep 13.

a Department of Microbiology, Faculty of Medicine , Kuwait University , Jabriya , Kuwait.

Introduction: Prevalence of TB and MDR-TB varies considerably among various regions of World Health Organization (WHO) and also among individual countries within each region. Many Middle Eastern countries have war/civil war-like situations, refugees from war-torn countries or dynamic expatriate population from TB endemic countries which will likely affect the END-TB strategy launched by the WHO in 2015. Areas covered: The data for each of 17 countries comprising the Middle East were analyzed for estimated incidence of TB, number of notified TB cases, mortality rate, and rate of MDR-TB in new and previously treated TB cases as reported by WHO. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14787210.2018.1
Publisher Site
http://dx.doi.org/10.1080/14787210.2018.1519393DOI Listing
September 2018
6 Reads

Treatment of tuberculosis infection in children.

Expert Rev Anti Infect Ther 2018 09 7;16(9):695-708. Epub 2018 Sep 7.

a Baylor College of Medicine , Houston , Texas.

Introduction: Identifying and treating children with tuberculosis (TB) infection in both low and high-TB burden settings will decrease the incidence of TB disease worldwide. Areas covered: This review covers each of the available TB infection treatment options for children based on effectiveness, safety, tolerability and treatment completion rates. Six to 9 months of daily administered isoniazid is no longer the treatment of choice for many children with TB infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1513324DOI Listing
September 2018
1 Read